Cargando…
Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
OBJECTIVE: This study aimed to examine the efficacy and safety of nepafenac ophthalmic suspension compared to placebo in the management of postoperative inflammation and ocular pain in Japanese patients undergoing cataract surgery. METHODS: This was a multicenter, randomized, double-masked, placebo-...
Autor principal: | Numaga, Jiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223346/ https://www.ncbi.nlm.nih.gov/pubmed/21932014 http://dx.doi.org/10.1007/s12348-011-0036-8 |
Ejemplares similares
-
Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
por: Singh, Rishi P, et al.
Publicado: (2017) -
Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Gaynes, Bruce I, et al.
Publicado: (2008) -
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
por: Nardi, M, et al.
Publicado: (2007) -
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018) -
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
por: Silverstein, Steven M.
Publicado: (2019)